Atty Dkt No. 80146.002 USN: 08/844,215 PATENT

I. AMENDMENTS

In the claims:

Please amend claims 31, 48 and 56 as follows:

31. (Amended) An isolated nucleic acid molecule encoding a human Fab molecule, comprising:

a first nucleotide sequence encoding a first polypeptide that is homologous to the binding portion of a $\gamma 1$ heavy chain variable region (V_H) of said human Fab molecule where said heavy chain region exhibits immunological binding affinity for a hepatitis C virus (HCV) E2 antigen; and

a second nucleotide sequence encoding a second polypeptide that is homologous to the binding portion of a κ light chain variable region (V_L) of said human Fab molecule where said light chain variable region exhibits immunological binding affinity for a hepatitis C virus (HCV) E2 antigen, wherein said Fab molecules have binding affinity greater than 1×10^7 M⁻¹ for HCV E2.

- 48. (Amended) An isolated nucleic acid molecule, comprising a first nucleotide sequence encoding a binding portion of a $\gamma 1$ heavy chain variable region (V_H) of a human Fab molecule obtained from a combinatorial library, wherein said Fab molecule exhibits immunological binding affinity greater than $1 \times 10^7 \, M^{-1}$ for a hepatitis C virus (HCV) E2 antigen.
- 56. (Amended) An isolated nucleic acid molecule, comprising a first nucleotide sequence encoding a binding portion of a κ light chain variable region (V_L) of a human Fab molecule obtained from a combinatorial library, wherein said Fab molecule exhibits immunological binding affinity greater than $1 \times 10^7 \, \text{M}^{-1}$ for a hepatitis C virus (HCV) E2 antigen.